Photo via Evening Standard

World’s first mRNA cancer jab for melanoma cuts risk of death by 42%

Read the original at Evening Standard ↗
Cite

Kirby, J. (2026, October 23). World’s first mRNA cancer jab for melanoma cuts risk of death by 42%. Evening Standard. https://www.standard.co.uk/news/science/world-moderna-experts-rollsroyce-london-b1302077.html

Dated from the outlet's own feed. Check the original for its byline.

Evening Standard · collected 2026-10-23 · by Jane Kirby

Quick Summary

A large trial has shown that a personalized mRNA cancer vaccine for melanoma reduces the risk of recurrence or death by 42% when used with immunotherapy. The study involved over 1,100 high-risk melanoma patients who had surgery to remove their tumors. This vaccine works by targeting specific markers on each patient’s tumor and activating an immune response against these unique cancer mutations. The combination therapy also increased two-year survival rates without recurrence from 70% to 82%.
Written by AI on 2026-10-23, from this article's own text only (the story summary below draws on all the coverage).
See how they differ ↓

AI analysis

Story summary

Moderna and MSD developed intismeran, a personalized mRNA-based vaccine, which when combined with Keytruda (pembrolizumab) reduced the risk of melanoma recurrence or death by 42% in patients two years after surgery. The trial included over 1,100 participants with high-risk melanoma that had been surgically removed. Intismeran targets up to 34 tumor neoantigens specific to each patient's tumor, enhancing the immune system’s ability to fight cancer. Although results are promising and could mark a turning point in personalized cancer treatment, longer-term studies are needed to confirm long-term benefits and impact on overall survival rates. The vaccine is currently experimental and not available on healthcare systems like NHS yet. Similar approaches are being tested for other cancers including kidney, bladder, and lung cancer. The detailed findings were initially scheduled to be presented at the European Society of Medical Oncology Congress but were released ahead of time due to data leaks. Lead researcher Professor Georgina Long from Melanoma Institute Australia described the results as "phenomenal" and potentially transformational for cancer treatment. Independent experts also view the outcome positively, though they emphasize the need for extended follow-up studies to establish definitive benefits in patient longevity.

Written for “mRNA Cancer Vaccine Breakthrough For Melanoma” on 2026-11-21, grounded in this article and the 7 other(s) covering the same event.

How they differ

8 outlets covered “mRNA Cancer Vaccine Breakthrough For Melanoma”.

What each outlet says

One AI summary per outlet of its latest article on this story, written from that article alone and checked against it. Open the article for the outlet's own words.

Evening StandardThis outlet23 Oct

A large trial has shown that a personalized mRNA cancer vaccine for melanoma reduces the risk of recurrence or death by 42% when used with immunotherapy. The study involved over 1,100 high-risk melanoma patients who had surgery to remove their tumors. This vaccine works by targeting specific markers on each patient’s tumor and activating an immune response against these unique cancer mutations. The combination…

World’s first mRNA cancer jab for melanoma cuts risk of death by 42% (this article)
The Independent22 Oct

ModernA’s mRNA cancer vaccine combined with Merck's immunotherapy reduced melanoma recurrence or death risk by 42%, according to a Phase 3 clinical trial involving over 1,100 patients. The study also showed a 38% reduction in the spread of cancer and revealed that 82.2% of patients receiving both treatments remained cancer-free after two years compared to 70% for those treated with Keytruda alone. ModernA plans to…

mRNA cancer vaccine slashes melanoma death or recurrence risk by 42% →
Toronto Star22 Oct

Moderna and Merck released results from a major study showing that an mRNA-based cancer vaccine called intismeran significantly reduces by 42% the risk of melanoma returning two years after surgery. The personalized vaccine, which targets unique gene mutations in each patient's tumor, was administered alongside standard post-surgery treatment to over 1,100 people with high-risk melanoma. At the end of the trial, 82%…

A novel mRNA cancer vaccine helps reduce the chances of melanoma patients' tumors returning →
Time23 Oct

Moderna and Merck announced on October 22 that their customized cancer vaccine for late-stage melanoma reduces recurrence or death risk by 42% over two years compared to standard treatment. The study involved more than 1,130 patients who had tumors surgically removed and were then given either the intismeran vaccine (along with Keytruda) or a placebo plus Keytruda. Intismeran uses mRNA technology to help immune…

A Personalized Cancer Vaccine Lowers Melanoma Recurrence by 42% →
Daily Mail23 Oct

Professor Georgina Long led a world-first cancer vaccine trial that significantly reduced the risk of melanoma recurrence or death by 42% compared to patients treated with only pembrolizumab (Keytruda). The study, involving 1,137 participants across 157 global sites, tested an individualised mRNA vaccine called intismeran, developed by Moderna and MSD. This breakthrough could revolutionize cancer treatment…

World-first cancer vaccine slashes death risk in stunning findings led by Aussie scientist →
ABC News (AU)23 Oct

Researchers led by Australia have developed a world-first cancer vaccine that significantly reduces the risk of melanoma recurrence by 42 percent, according to phase 3 trial results. The study, set to be published in the New England Journal of Medicine, involved 1,137 patients and compared personalized mRNA-based vaccines combined with immunotherapy against immunotherapy alone. The treatment identifies unique…

Australia at the heart of 'transformational' cancer vaccine breakthrough →
Show 2 more outlets
BBC23 Oct

A new personalized cancer vaccine, when combined with an existing immunotherapy drug called Keytruda, has shown significant promise in reducing the recurrence and spread of melanoma by 42% and 38%, respectively, over two years. This trial involved more than 1,100 patients who had their tumors surgically removed. The vaccine, named Intismeran, uses mRNA technology similar to that used in some COVID vaccines, tailored…

First personalised cancer vaccine cuts risk of disease returning in major trial →
CBC23 Oct

Moderna and Merck released results from a major study showing their mRNA-based personalized cancer vaccine, intismeran, significantly reduces the risk of melanoma recurrence by 42% when used in conjunction with an existing treatment. The vaccine is tailored to each patient based on unique genetic mutations found in their tumor, leveraging mRNA technology similar to that used in COVID-19 vaccines. Dr. Hussein Tawbi…

A novel mRNA cancer vaccine helps cut the chances of melanoma tumor recurrence in major study →

Where they agree and split

Framing

How the first headlines put it

Stated as fact7
The headlines (7)

mRNA cancer vaccine slashes melanoma death or recurrence risk by 42% The Independent · stated as fact

A novel mRNA cancer vaccine helps reduce the chances of melanoma patients' tumors returning Toronto Star · stated as fact

A Personalized Cancer Vaccine Lowers Melanoma Recurrence by 42% Time · stated as fact

World-first cancer vaccine slashes death risk in stunning findings led by Aussie scientist Daily Mail · stated as fact

Australia at the heart of 'transformational' cancer vaccine breakthrough ABC News (Australia) · stated as fact

First personalised cancer vaccine cuts risk of disease returning in major trial BBC · stated as fact

World’s first mRNA cancer jab for melanoma cuts risk of death by 42% Evening Standard · stated as fact

The full story: what happened, how it changed, and all 8 articles →

Compared with similar articles

This article reads unscored and hedges 4% of its claims. Each row says how that neighbour differs.
The Independent
Hedges 0 of 16 claims Outlet record 59/100
TIME
Hedges 3 of 28 claims Outlet record 60/100
Daily Mail
Hedges 1 of 10 claims Outlet record 69/100
ABC News (AU)
Hedges 3 of 34 claims Outlet record 67/100
BBC News
Hedges 2 of 28 claims Outlet record 65/100
CBC News
Hedges 3 of 46 claims Outlet record 72/100
Toronto Star
Hedges 3 of 35 claims Outlet record 64/100

Story

mRNA Cancer Vaccine Breakthrough For Melanoma
Health · 8 article(s) covering the same event. Compare every outlet's account →
How this article was measured signals, leaning charts, publisher record, byline, topics and claims

Signals How these are calculated →

Claims extracted
25
sentences that state something as happening or true
Uncertain
4%
1 of 25 hedged ("reportedly", "may", "according to")
Leaning
not political
takes no side on a contested political question
Publisher signals
64/100
Evening Standard's corrections and hedging, across everything collected from it. Not a measure of accuracy.
Outlets on this story
8
Health
Same framing elsewhere
1
articles that frame the event the way this one does
Analyzed 2026-10-23 · how these are computed

How this is being covered How these are calculated →

Article leaning vs. publisher reliability
Source leaning vs. consistency

Publisher

Evening Standard · 11094 article(s) · 82 correction(s) detected
Running correction rate · 82 correction(s)

Who wrote this

Jane Kirby
17 article(s) here · 1 carrying a prediction
The patient, who is thought to be a healthcare worker, is expected to be brought back to the UK later on Thursday, the Press Association understands.
At least 60 minutes per month inside an art gallery or museum could help cut depression, lower stress and improve health, according to the evidence-backed study from the Art Fund charity.
“We would also encourage people to think about neighbours, pets and wildlife by letting people know about displays in advance and considering lower-noise fireworks where possible.”
There is currently no confirmed timeline for when this might happen.”
A new clinical trial could dramatically speed up the discovery of treatments for Alzheimer’s disease.
The Royal Marsden Centre for Cancer Genomics is the first of its kind to deliver a new generation of cancer diagnostics known as composite biomarker testing and will work with doctors and patients across the UK.
The parents of a 12-year-old girl who died from an allergic reaction after drinking a contaminated milkshake have said she “will never be forgotten” as an inquest into her death concluded.
“Staff are already seeing the ominous early signs of pressure, with more patients coming to A&E with flu and other respiratory viruses than usual for this time of year, and unfortunately many people are still waiting longer than we would like them to.
He said around 550 deaths every week across all of England, Wales and Northern Ireland may be caused by overcrowding in emergency departments.
He said around 550 deaths every week across all of England, Wales and Northern Ireland may be caused by overcrowding in emergency departments.
Also by Jane Kirby
Nothing else under this byline is closely related to this article, so these are simply their most recent.
All 17 articles by Jane Kirby →

Topics

Covid Keytruda Melanoma Focus

Subjects

Heather Shaw PERSON · 1× Melanoma Focus ORG · 1× NHS ORG · 1× Susanna Daniels PERSON · 1× UCLH ORG · 1×

Narrative

Consultant medical oncologist Heather Shaw, from University College London Hospital (UCLH), who was the UK chief investigator for the trial, said the results were “very encouraging” for people with high-risk melanoma. “This is an important step forward, but we still need longer follow-up to understand whether the benefit lasts and whether patients live longer. “The treatment also caused more side-effects, particularly fever and tiredness. “The vaccine remains an experimental treatment and is not currently available on the NHS.
framing: assertive · carried by 1 article(s) · first seen 2026-10-23
There is currently no confirmed timeline for when this might happen.”
2026-10-23 · Evening Standard
World’s first mRNA cancer jab for melanoma cuts risk of death by 42% · assertive framing

Claims (25 extracted, 1 hedged)

The world’s first personalised mRNA cancer jab for melanoma has cut the risk of patients dying or cancer returning by 42% when combined with immunotherapy, a large trial shows. asserted
trial → cut → immunotherapy
The drug, which was given to patients in the UK and worldwide, is also being tested in other cancers, including kidney, bladder and lung cancer. asserted
which → give → cancer
It cut the risk of recurrence or death in melanoma patients by 42% two years later, compared with Keytruda alone. asserted
It → cut → Keytruda
The data also showed that the dual therapy cut the risk of cancer spreading or death by 38%. asserted
therapy → show → %
About 82% of patients on the combination were still alive without melanoma returning two years later, compared with 70% of those who received Keytruda alone, the firms said. asserted
firms → return → Keytruda
The study included more than 1,100 people with high-risk melanoma that had been surgically removed. asserted
that → include → melanoma
It works by triggering the immune system so it can fight back against the patient’s specific type of cancer and tumour. asserted
it → work → cancer
The vaccine targets tumour neoantigens, which are expressed by tumours in a particular patient. asserted
which → target → patient
These are markers on the tumour which can potentially be recognised by the immune system. asserted
which → recognise → system
The jab carries coding for up to 34 neoantigens and activates an anti-tumour immune response based on the unique mutations in a patient’s cancer. asserted
jab → carry → cancer
In order to create the jab, a sample of tumour is removed during the patient’s surgery, followed by DNA sequencing and the use of artificial intelligence. asserted
sample → create → intelligence
Susanna Daniels, chief executive of Melanoma Focus in the UK, said: “These positive trial results represent a really exciting milestone in melanoma skin cancer treatment. asserted
results → say → treatment
Read More “With melanoma accounting for over 20,000 new diagnoses and 2,600 deaths in the UK each year, innovations that help prevent recurrence and stop the cancer spreading offer vital new hope for melanoma patients.” asserted
cancer → read → patients
“Cancer vaccines have been researched for many years, but advances in genetic sequencing, immunotherapies and mRNA technology, including experience gained from Covid vaccines, have transformed what is possible. asserted
what → research → vaccines
“What is particularly exciting here is that this vaccine is personalised, using information from each patient’s own tumour to identify targets that are specific to their cancer. asserted
that → personalise → cancer
“It essentially trains the immune system to recognise those cancer cells as a threat and attack them, while pembrolizumab helps release the brakes on the immune response. asserted
pembrolizumab → train → response
“This is a large phase III trial, so it provides much stronger evidence than we have previously had that a personalised cancer vaccine can make a meaningful difference to patients.” asserted
vaccine → provide → patients
He said vaccines are being investigated in many other cancers, including cancers that are very difficult to treat and do not respond to immunotherapy. asserted
that → say → immunotherapy
“The challenge now is working out which cancers and which patients are most likely to benefit, and which are the best vaccine targets to go for,” he said. asserted
he → work → ?
“We’re closer to cancer vaccines becoming part of routine treatment than we’ve ever been, but they are not going to replace existing treatments across the board. asserted
they → ’re → board
“The more realistic prospect is that they become another powerful tool that we can combine with treatments such as immunotherapy.” asserted
we → become → immunotherapy
“It is a large, randomised, double-blind, well-controlled study, representing the highest standard of clinical evidence. asserted
It → control → evidence
Consultant medical oncologist Heather Shaw, from University College London Hospital (UCLH), who was the UK chief investigator for the trial, said the results were “very encouraging” for people with high-risk melanoma. “This is an important step forward, but we still need longer follow-up to understand whether the benefit lasts and whether patients live longer. “The treatment also caused more side-effects, particularly fever and tiredness. “The vaccine remains an experimental treatment and is not currently available on the NHS. asserted
vaccine → say → NHS
“We are some way from being able to offer it routinely to patients, as further approval and assessment processes need to take place. asserted
processes → offer → place
There is currently no confirmed timeline for when this might happen.” uncertain
this → be → ?
Give feedback · no sign-in needed

No sign-in needed for now. Your note is sent without a name, so it cannot be answered.

History Support